by Mark Curtis | Jul 21, 2014
. The Centre for Commercialization of Regenerative Medicine (CCRM) just finished hosting the 7th annual Business of Regenerative Medicine course here in Toronto, which saw many notable figures in the space come to weigh-in on a number of critical issues relevant to...
by Stacey Johnson | May 16, 2014
. Last November, I wrote about CCRM’s new Regenerative Medicine Video Network and featured an original video with Dr. Stephen Minger, Chief Scientist, Cellular Sciences GE Healthcare Life Sciences in the UK. If you enjoyed his industry perspective and insights on...
by Sara M. Nolte | Apr 8, 2014
> The thing that is so intriguing about cancer stem cells (CSCs), from a cancer researcher’s perspective, is their powerful potential as therapeutic targets. While CSCs can create or regenerate tumours (causing relapse in some patients despite our best efforts to...
by Mark Curtis | Jan 13, 2014
. Welcome to your Regenerative Medicine Deal Review for the month of December. Toronto-based Stem Cell Therapeutics successfully executed on a financing of $33 million, while Pluristem announces it is moving forward on a licensing agreement with Korea-based CHA....
by Angela C. H. McDonald | Sep 11, 2012
You don’t have to follow pharmaceutical industry news to know that this summer has been a disappointing one for Alzheimer’s research. Many major media outlets covered the failure of potential Alzheimer’s drug bapineuzumab (Pfizer/Johnson & Johnson) in Phase II/III...
Comments